US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
You may also like

WEEX Live mode: Monitor 20 trading pairs at once and trade like a pro

Morning Report | Secret Network loses $4.67 million due to cross-chain vulnerability; Michael Saylor releases Bitcoin Tracker information again, may disclose increased holdings data next week

Kalshi's biggest competitor is not Polymarket

WEEX Makes Affiliate Access Easier on the Web and in the App

Customize Your Spot Trading Page: Drag Modules and Move the Order Panel Where You Want It

Perp DEX: The Next Generation Exchange "War"

10 Counterintuitive Insights on Latin American Payments

The AI gamble of mining companies: Valuations enter a phase of differentiation, and it's hard to turn the tide

A letter from Alliance to entrepreneurs: Written on the occasion of Cursor selling for 60 billion dollars

Stablecoins Finally Find Real Returns: On-Chain Reinsurance Re Explained | Interview with Re Founder Karan Saroya

The impossible triangle is simply a pseudo problem

Will MicroStrategy fall into a death spiral? What will the macro trend be in the second half of the year?

Blockchain Capital Partner: The Core Secret of Arbitrage

STRC unanchored by 11%, can the perpetual motion machine of Strategy still operate?

Bitcoin Market Analysis 2026: Can BTC Reach $150K by Year-End?

Bitcoin ETF Outflows Hit a Record $4.4 Billion: What Are Traders Doing With Their Cash?

WEEX App Just Got Smarter – New Tabs for Faster Trades & Easy Asset Management


